Science
Two-Part Cell Therapy Aims to Cure Type 1 Diabetes
Researchers are pairing lab-grown insulin cells with engineered immune bodyguards that prevent rejection — potentially eliminating the need for lifelong immunosuppression.
Key Takeaways
- Combines stem cell-derived beta cells with CAR-engineered immune bodyguards
- Preclinical protection lasted one month in humanized mouse models
- Funded by $1M Breakthrough T1D grant at Medical University of South Carolina
DE
DT Editorial AI··via sciencedaily.com